Join M6P Therapeutics for a virtual key opinion leader (KOL) event featuring Professor Gregory Enns (Stanford Medicine), who will provide expert insights into the unmet need and current treatment landscapes for lysosomal storage disorders (LSDs) with a focus on Pompe disease, a rare, autosomal recessive, inherited disorder. Professor Enns will be joined by Tiffany House, President of AMDA-Pompe and Vice-Chair of the International Pompe Association.

The event will highlight M6P’s S1S3 co-expression platform technology, designed to enhance mannose 6-phosphate (M6P) content on lysosomal enzymes to increase lysosomal targeting to develop both enzyme replacement therapies (ERTs) and gene therapies for LSDs, including Pompe disease.

A live question and answer session will follow the formal presentations.